logo
Kraft Heinz products getting no-dye makeover

Kraft Heinz products getting no-dye makeover

Yahoo14-07-2025
Condiment giant Kraft Heinz said it won't add artificial coloring to any new product it launches in the U.S., starting now. And in compliance with plans by U.S. Health and Human Services Secretary Robert F. Kennedy, Jr., the company hopes to get rid of all artificial dyes in U.S.-sold products before 2028.
The announcement was made Tuesday morning in a news release that said nearly 90% of the company's products in the U.S. are already free of artificial colors, which are called 'Food, Drug & Cosmetic' colors by the U.S. Food and Drug Administration.
For the products that do contain artificial coloring, the company said it has 'invested significant resources, mobilizing a team to address this complex challenge with a three-pronged approach':
Kraft Heinz is removing colors 'not critical to the consumer experience.'
It's replacing artificial colors with natural colors.
For its third alternative, the company is 'reinventing new colors and shades where matching natural colors are not available.'
Kraft Heinz brands include Jell-O, Philadelphia Cream Cheese, Capri Sun, Kool-Aid, Grey Poupon, Honig, Oscar Mayer, Classico, Lunchables and Quero, among others.
Pedro Navio, North America president of Kraft Heinz, said in the release that the company is more than 150 years old and its product line and recipes are always 'evolving.' He noted they took the artificial colors, preservatives and flavors out of their Kraft Mac & Cheese in 2016.
'Our iconic Heinz Tomato Ketchup has never had artificial dyes — the red color comes simply from the world's best tomatoes," he said.
The company also emphasized how much of its product line comes from U.S. sources. 'Today, Kraft Heinz sources the most tomatoes in the U.S., all grown in California for products like Heinz Tomato Ketchup. Claussen pickles (cucumbers) are grown in Ohio and Michigan; Ore-Ida potatoes are grown in Idaho; the dairy for Philadelphia cream cheese comes from farms in Upstate New York,' per the release.
Other companies are also eliminating artificial dyes. Reuters reported those include W.K. Kellogg and Tyson Foods, which 'have been working on reformulating existing products and introducing new items without artificial dyes.'
The article added that Walmart-owned Sam's Club announced earlier this month that it was getting rid of 40 ingredients, 'including artificial colors and aspartame,' from its Member's Mark brands by the end of 2025.
States are also taking steps. California, West Virginia and Virginia have said no to artificial dyes in food. And the Environmental Working Group has reported that dozens of other states are looking at banning artificial coloring and different additives, as well.
Deseret News reported in April that Kennedy was going to ban eight petroleum-based artificial food dyes from use in the American food supply. He said they would be eliminated within the next two years. The announcement, made by video, told food manufacturers to choose natural alternatives.
In the video, Kennedy said wryly that if people want to consume petroleum, 'they should add it themselves at home.'
Per Deseret News, 'Kennedy is focusing on the other eight artificial food dyes, which the Center for Science in the Public Interest calls 'a rainbow of risks.' Those eight are Blue No. 1 and Blue No. 2, Citrus Red No. 2, Green No. 3, Orange B, Red No. 40, Yellow No. 5 and Yellow No. 6."
The FDA had already said to stop using red dye No. 3. Authorization for Citrus Red No. 2 and Orange B are soon to be revoked, which will also happen to the remaining six petroleum-based dyes by year's end.
The driving force behind the ban has been health risk, with some research linking several of the dyes to possible tumor development and neurotoxicity in animal studies. There have been reported worries that had potential risk for attention deficit hyperactivity disorder, as Deseret News reported. There are also concerns the dyes could increase the risk of certain cancers.
Food manufacturers have said there's not strong evidence of health risks, but Kennedy's team has countered that any risk isn't worth it. And other countries are also taking steps.
Per The New York Times, Froot Loops in Canada are colored by blueberries and carrots, while the U.S. version is colored by Red No. 40, Yellow No. 5 and Blue No. 1. Many artificial dyes in food are banned in the European Union.
CNN reported that Kraft Heinz's action 'may push rivals to speed up efforts to phase out artificial coloring.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life
How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life

Business Insider

time5 hours ago

  • Business Insider

How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life

Biopharma giant Johnson & Johnson's (JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving the market a clear signal that it's reigniting growth with practically flawless numbers—a potential turning point for the second half of the year. The upwardly revised guidance and expectations for strong margin expansion, despite lingering litigation concerns, have brought fresh optimism to the stock and appeased shareholders clamoring for added value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. While the stock isn't as discounted as it was earlier this year, valuations still look reasonable. Given JNJ's strong compounding potential and this renewed bullish momentum, I see it as a Buy. How J&J's Strong Quarter Sets the Stage for Growth Johnson & Johnson stock has been rangebound for years, weighed down by a mix of factors, including a massive wave of lawsuits claiming its talc-based baby powder caused cancer due to asbestos contamination, as well as expiring drug patents, such as its blockbuster Stelara losing exclusivity. Last but not least is sluggish growth and an eroded safe-haven reputation, since legacy consumer brands like Tylenol, Listerine, and Band-Aid have low growth and face margin pressure from cheap competition. According to TipRanks data, JNJ has underperformed the S&P quite considerably since 2024. Johnson & Johnson's latest Q2 earnings may mark a true inflection point toward more consistent alpha generation. The company delivered exactly what it needed— beating both earnings and revenue expectations —while issuing a notable upward revision to guidance: an additional $2 billion in forecasted sales and $0.25 more in projected EPS. For a pharma giant like J&J, that's a clear signal of renewed momentum following a prolonged period of litigation-related overhang. Management also reaffirmed its full-year outlook for a 300-basis-point improvement in operating margin, raising it from approximately 25.4% to 28.4%. Notably, the quarter wasn't just about numbers. J&J reported compelling 5-year trial results for its multiple myeloma immunotherapy—an encouraging sign in the fight against a challenging cancer. The company also set an ambitious goal: to become the global leader in oncology by 2030, with a target of over $50 billion in cancer drug sales. With a potential $5 billion peak opportunity in bladder cancer and a strong pipeline aimed at offsetting losses from aging blockbusters, J&J is signaling that real innovation is back at the forefront. Breaking Free from the Margin Squeeze While markets often reward margin expansion, Johnson & Johnson looks especially well-positioned to benefit going forward. In addition to raising full-year earnings guidance, the company also delivered positive updates on cost pressures— halving its expected tariff impact from $400 million to $200 million and projecting a $1.1 billion tailwind from favorable currency shifts as the U.S. dollar weakens. The reduced tariff burden is primarily attributed to the MedTech division, which is more exposed to global supply chains and international manufacturing than the pharmaceutical segment. That's a clear tailwind for margins and future profitability. It's also important to note how strategic portfolio decisions have helped set the stage for this improvement. The 2023 spin-off of Kenvue—essentially the entire Consumer Health business—removed a lower-margin segment from the mix, sharpening J&J's focus on higher-margin areas. This move highlights the company's commitment not only to defending margins but also to actively growing them. In today's market, stability alone isn't enough—investors are looking for real margin expansion, and Johnson & Johnson seems intent on delivering. Analysts have responded by raising their EPS estimates for 2025 and 2026 by about 2% compared to before Q2 earnings. They now expect full-year EPS in 2025 to hit $10.86 —an 8.7% increase from last year—and to reach $11.34 in 2026, representing an annual growth rate of 4.4%. Reasonable Valuation with Growth on the Horizon Johnson & Johnson is a vast, stable, and diversified company, so its valuation tends to reflect relative stability rather than wild growth. Looking at its forward earnings multiple, currently around 15.5x, it's basically in line with the five-year average. This is well above the lows seen earlier this year, when it traded as low as 11x forward earnings in January. To me, this suggests the valuation isn't necessarily cheap, but it's reasonable. Comparing J&J's current earnings multiples over the last twelve months to its main peers, the 17.5x P/E ratio sits close to the sector average. Except for Merck & Co. (MRK), J&J is actually one of the more discounted names in the group. Finally, with a dividend yield of almost 3%, the stock no longer appears exuberant, and the yield isn't particularly compelling—especially when compared to the 10-year U.S. Treasury yield. However, J&J's payout ratio is typically safe, at around 50% of earnings, which helps build shareholder trust. Additionally, the market is now anticipating a more positive growth trajectory following the recent upward revisions to guidance, both last quarter and earlier this year. Is JNJ Stock a Buy, Hold, or Sell? Wall Street sentiment on Johnson & Johnson remains mixed, with more caution than conviction among analysts. Of the 19 analysts who have issued ratings over the past three months, nine are bullish, while the remaining ten are neutral. The average price target stands at $176.35, suggesting a modest upside of approximately 4.3% from the current share price. Johnson & Johnson Positioned for Consistent Alpha Generation Johnson & Johnson has, in my view, successfully restored market confidence in both its innovation pipeline and cost discipline—key pillars that could drive renewed growth and support reliable shareholder returns for decades to come. For long-term investors, initiating a position now is essentially a bet on a proven dividend combined with steady capital appreciation—an attractive formula that has historically outperformed the broader market. While the stock appears fairly valued at current levels, it offers compelling potential for compounding returns and consistent alpha generation in the years ahead.

Kraft Heinz's Q2 Earnings on Horizon: What Surprise Awaits Investors?
Kraft Heinz's Q2 Earnings on Horizon: What Surprise Awaits Investors?

Yahoo

time15 hours ago

  • Yahoo

Kraft Heinz's Q2 Earnings on Horizon: What Surprise Awaits Investors?

The Kraft Heinz Company (KHC) is likely to register a decline in both the top and bottom lines when it reports second-quarter 2025 earnings on July 30. The Zacks Consensus Estimate for revenues is pegged at $6.3 billion, indicating a 2.9% drop from the prior-year quarter's reported figure. The consensus mark for quarterly earnings has remained unchanged in the past 30 days at 64 cents per share, projecting a decline of 18% from the figure reported in the year-ago quarter. KHC has a trailing four-quarter earnings surprise of 4.8%, on average. Factors Likely to Impact KHC's Upcoming Results Kraft Heinz has been facing headwinds in its volume performance, which have been exerting pressure on its top-line growth. The company has been grappling with evolving consumer behavior and macro-economic pressures like tariffs and inflation, alongside weakness in the U.S. Away from Home segment. These persistent challenges pose a threat to Kraft Heinz's organic sales, ultimately impacting overall revenues. Our model suggests a 3.2 percentage point year-over-year decline in volume/mix for the second quarter of 2025. As a result, we project a 3.2 percentage point drop in organic net sales during the same period. In addition to weak volume trends, Kraft Heinz has also been dealing with margin pressure. The downside can be attributed to unfavorable volume/mix shifts, rising manufacturing and procurement costs, and unfavorable foreign currency impacts. We expect the company's adjusted gross margin to contract 190 basis points year over year, reaching 33.6% in the second quarter of 2025. Kraft Heinz has been strategically driving growth through effective pricing, operational efficiencies and innovation. Kraft Heinz's Brand Growth System is scaling while expanding in emerging markets. Kraft Heinz Company Price and EPS Surprise Kraft Heinz Company price-eps-surprise | Kraft Heinz Company Quote Earnings Whispers for KHC Stock Our proven model predicts an earnings beat for Kraft Heinz this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chance of an earnings beat. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Kraft Heinz currently has an Earnings ESP of +0.31% and a Zacks Rank of 3. More Stocks With the Favorable Combination Here are a few more companies, which according to our model, have the right combination of elements to beat on earnings this reporting cycle. Freshpet (FRPT) currently has an Earnings ESP of +40.68% and a Zacks Rank of 3. The company is likely to register growth in the top line when it reports second-quarter 2025 numbers. The consensus mark for revenues is pegged at $267.7 million, which indicates an increase of 13.8% from the figure reported in the year-ago quarter. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Freshpet's quarterly earnings per share of 12 cents implies a sharp rise from the loss per share of three cents reported in the year-ago quarter. The consensus mark has gone down a penny in the past 30 days. FRPT has a trailing four-quarter earnings surprise of 22.3%, on average. Anheuser-Busch InBev SA/NV (BUD), alias AB InBev, has an Earnings ESP of +7.06% and a Zacks Rank of 3 at present. BUD is likely to register a bottom-line decline when it releases second-quarter 2025 results. The consensus estimate for AB InBev's quarterly earnings has risen a couple of cents in the past 30 days to 89 cents per share, implying a drop of 1.1% from the year-ago quarter's number. The Zacks Consensus Estimate for quarterly revenues is pegged at $15.3 billion, which implies a drop of 0.5% from the figure reported in the year-ago quarter. BUD delivered an earnings surprise of 10.9%, on average, in the trailing four quarters. Monster Beverage (MNST) currently has an Earnings ESP of +0.37% and a Zacks Rank of 3. The company is expected to register growth in its top and bottom lines when it reports second-quarter 2025 results. The Zacks Consensus Estimate for MNST's quarterly earnings has moved down a penny in the last 30 days to 48 cents per share, indicating 17.1% growth from the year-ago quarter's number. The consensus estimate for Monster Beverage's quarterly revenues is pegged at $2.1 billion, implying a rise of 9.4% from the figure in the prior-year quarter. MNST reported a negative earnings surprise of 4.1%, on average, in the trailing four quarters. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Freshpet, Inc. (FRPT) : Free Stock Analysis Report Anheuser-Busch InBev SA/NV (BUD) : Free Stock Analysis Report Monster Beverage Corporation (MNST) : Free Stock Analysis Report Kraft Heinz Company (KHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data

Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch.
Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch.

Yahoo

timea day ago

  • Yahoo

Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch.

Key Points Warren Buffett's company Berkshire Hathaway has never paid a dividend. That hasn't stopped Buffett and his team from investing in several high-yielding stocks. Dividends can make stocks with long turnarounds ahead much more attractive. 10 stocks we like better than Realty Income › Warren Buffett's company Berkshire Hathaway has never paid shareholders a dividend while under Buffett's leadership. The primary reason is because Buffett believed he could find better ways to invest the capital -- and he was definitely right. Berkshire's returns have crushed the broader benchmark S&P 500 index over many decades, and many people regard Buffett as the best investor of all time. While never paying a dividend, Buffett and his team of investors have never been afraid to invest in high-yielding stocks. They often look for companies in turnaround mode -- but they pay nice dividends to compensate investors for their time. Buffett and Berkshire own nine high-yielding stocks. Here's the best of the bunch. Three are top 20 positions Three of Berkshire's top 20 equity holdings warrant attention: Kraft Heinz (NASDAQ: KHC), Sirius XM (NASDAQ: SIRI), and Chevron (NYSE: CVX), which have dividend yields of roughly 5.6%, 4.5%, and 4.5%, respectively. Kraft Heinz is largely viewed as one of Buffett's most disappointing investments. Buffett first acquired a stake in Heinz in 2013 when he partnered with the Brazilian private equity firm 3G to buy the company. The two parties then worked together in 2015 to merge Kraft and Heinz in a $49 billion transaction. Since then, the stock hasn't performed well and is down another roughly 4.7% this year (as of July 23). More recently, Berkshire has given up its seats on the board at Kraft Heinz and there is speculation that the company may soon break up. Sirius is a position that Berkshire added to heavily in recent years. The large digital audio company, which owns Sirius XM and the Pandora music streaming business, is considered one of the few legal monopolies but it looks like it will have a lengthy turnaround ahead after declining 30% during the past year. The large U.S. oil and gas producer Chevron is part of a growing number of energy assets that Buffett and Berkshire have gobbled up in recent years. Berkshire clearly thinks the price of oil is going higher long term and may also view energy as an asset that will be in high demand during the coming decades. Chevron, which is down about 4% during the past year, has increased its dividend for 38 straight years and is certainly a dividend gem. Buffett's "secret portfolio" While you can't see Buffett's other seven high-yielding dividend stocks in Berkshire's filings, the company, in essence, has a "secret portfolio" in New England Asset Management (NEAM), which is not directly managed by Berkshire. In 1998, Berkshire came to own NEAM via its acquisition of General Re, which bought NEAM in 1995. Here are the seven high-yielding dividend stocks in NEAM and their perspective dividend yields (as of July 23): Golub Capital BDC (NASDAQ: GBDC) -- 10.2% Ares Capital (NASDAQ: ARCC) -- 8.4% Pfizer -- 6.8% Realty Income (NYSE: O) -- 5.6% Bristol Myers Squibb -- 5.2% Campbell's -- 4.8% Lamar Advertising -- 5% You'll notice a few themes in this bunch. Golub and Ares are business development companies (BDCs), which are known for paying high dividends due to their unique corporate structure as regulated investment companies. If these companies pay out at least 90% of their taxable income to shareholders through dividends, they avoid paying corporate taxes. As a real estate investment trust (REIT), Realty Income has the same deal. Pfizer and Bristol Myers are both pharmaceutical stocks, which can also pay hearty dividends. The best of the bunch Although its stock has not performed great during the past five years, Realty Income is the best of the bunch, in my opinion, especially from an income perspective. Sure, there are some REITS and BDCs with much higher yields, but their payouts can fluctuate with earnings. As a REIT, Realty Income stands out in terms of consistent performance. It mainly operates a triple-net-lease model in which it rents its properties to tenants who pay maintenance and upgrade costs, property taxes, and insurance. In return, tenants may be able to negotiate more favorable terms and also have more control over the spaces they rent, which can be helpful for businesses. Realty Income specifically focuses on non-discretionary, low-price-point, and service-oriented tenants like 7-Eleven, Dollar General, and Walgreens, among many others. The company is also getting involved in higher-growth sectors, like gaming and data centers, while also looking to expand its geographic reach in Europe. As for the dividend, Realty Income is as reliable as they come, which is perhaps why the company's slogan is, "The Monthly Dividend Company." Since going public in 1994, Realty Income has increased its quarterly dividend for 110 consecutive quarters. The dividend has grown at a 4.3% compound annual growth rate and looks very sustainable. In 2024, Realty Income paid out about $3.13 of dividends per share and generated adjusted funds from operations (AFFO), which is basically like cash flow for REITs, of $4.19, giving it room to spare. Should you buy stock in Realty Income right now? Before you buy stock in Realty Income, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!* Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Bristol Myers Squibb, Chevron, Pfizer, and Realty Income. The Motley Fool recommends Campbell's and Kraft Heinz. The Motley Fool has a disclosure policy. Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store